REG - Fusion Antibodies - Grant of patent in Japan

Fusion AntibodiesAnnouncement

Mon 11:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260511:nRSK8115Da&default-theme=true

RNS Number : 8115D  Fusion Antibodies PLC  11 May 2026

11 May 2026

Fusion Antibodies plc

("Fusion" or the "Company")

 

Grant of patent in Japan

Grant strengthens antibody discovery platform and licensing opportunities

 

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody
discovery, engineering and supply for both therapeutic drug and diagnostic
applications, announces the Company's patent application no. 2021-519644 has
been formally granted by the Japan Patent Office (the "Japanese Patent
Office") under Japanese Patent no. 7853096 (the "Patent").

 

The Patent, entitled "Antibody Library and Method", covers two families of
antibodies, and the method for the design of such antibody libraries. The
Patent is expected to be complementary to Fusion's offering to provide "Opti"
designed antibody libraries for a range of applications including: Antibody
Discovery; Affinity Maturation; and Sequence Optimisation.

 

The Company is also progressing additional patent applications in respect of
the OptiMAL® Library in Japan and several other territories worldwide
including Europe and China.

 

Richard Buick, CSO of Fusion, said: "I am really pleased that the Japanese
Patent Office has granted this approval. This confirms our unique approach to
antibody library design and protects these families of antibodies. Furthermore
with this recognition in Japan, we are continuing to advance our global
strategy to expand the reach and impact of our Opti designed antibody
technologies."

 

Adrian Kinkaid, CEO of Fusion, said: "This excellent news lays the foundations
for potential future licensing deals and complements our strategy to protect
OptiMAL®. This patent marks an important milestone in strengthening our
platform and reinforces our commitment to delivering high quality antibody
solutions for both therapeutic and diagnostic innovation. With this
significant step, we are accelerating our mission to transform how antibodies
are designed, discovered, and optimised worldwide."

 

Enquiries:

 

 Fusion Antibodies plc                                           www.fusionantibodies.com
 Adrian Kinkaid, Chief Executive Officer                         Via Walbrook PR

 Stephen Smyth, Chief Financial Officer

 Allenby Capital Limited                                         Tel: +44 (0)20 3328 5656
 James Reeve/Vivek Bhardwaj (Corporate Finance)

 Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)

 Shard Capital Partners LLP
 Damon Heath (Joint Broker)                                      Tel: +44 (0)207 186 9952

 Walbrook PR                                                     Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
 Anna Dunphy                                                     Mob: +44 (0)7876 741 001

 

Investor
Hub
 
 

We encourage all investors to share questions on this announcement via our
investor hub https://investorhub.fusionantibodies.com/link/rJaa9e
(https://investorhub.fusionantibodies.com/link/rJaa9e)

 

 

About Fusion Antibodies plc

 

Fusion is a Belfast based contract research organisation ("CRO") providing a
range of antibody engineering services for the development of antibodies for
both therapeutic drug and diagnostic applications.

 

The Company's ordinary shares were admitted to trading on AIM on 18 December
2017. Fusion provides a broad range of services in antibody generation,
development, production, characterisation and optimisation. These services
include antigen expression, antibody production, purification and sequencing,
antibody humanisation using Fusion's proprietary CDRx (TM) platform and the
production of antibody generating stable cell lines to provide material for
use in clinical trials. Since 2012, the Company has successfully sequenced
and/or expressed over 750 antibodies and successfully completed over 250
humanisation projects and has an international, blue-chip client base, which
has included eight of the top 10 global pharmaceutical companies by revenue.

 

The Company was established in 2001 as a spin out from Queen's University
Belfast. The Company's mission is to enable pharmaceutical and diagnostic
companies to develop innovative products in a timely and cost-effective manner
for the benefit of the global healthcare industry. Fusion Antibodies provides
a broad range of services in antibody generation, development, production,
characterisation and optimisation.

 

Fusion Antibodies growth strategy is based on combining the latest
technological advances with cutting edge science to deliver new platforms that
will enable Pharma and Biotech companies get to the clinic faster, with the
optimal drug candidate and ultimately speed up the drug development process.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSFFFSFEMSESI



            Copyright 2019 Regulatory News Service, all rights reserved